Lyra Therapeutics Inc
LYRA26.010USD
+21.080+427.59%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.71BCap. mercado
PérdidaP/E TTM
Más Datos de Lyra Therapeutics Inc Compañía
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Información de la empresa
Código de la empresaLYRA
Nombre de la empresaLyra Therapeutics Inc
Fecha de salida a bolsaMay 01, 2020
Fundada en2005
Director ejecutivoDr. Maria Palasis, Ph.D.
Número de empleados30
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 01
Dirección480 Arsenal Way
CiudadWATERTOWN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02472
Teléfono16173734600
Sitio Webhttps://lyratherapeutics.com/
Código de la empresaLYRA
Fecha de salida a bolsaMay 01, 2020
Fundada en2005
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Harlan W. Waksal, M.D.
Dr. Harlan W. Waksal, M.D.
Executive Chair and Chairperson of the Board
Executive Chair and Chairperson of the Board
10.74K
--
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Dr. Richard Nieman, M.D.
Dr. Richard Nieman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R (Jim) Tobin
Mr. James R (Jim) Tobin
Lead Independent Director
Lead Independent Director
--
--
Ms. C. Ann Merrifield
Ms. C. Ann Merrifield
Independent Director
Independent Director
--
--
Mr. W. Bradford Smith
Mr. W. Bradford Smith
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Harlan W. Waksal, M.D.
Dr. Harlan W. Waksal, M.D.
Executive Chair and Chairperson of the Board
Executive Chair and Chairperson of the Board
10.74K
--
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Dr. Richard Nieman, M.D.
Dr. Richard Nieman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R (Jim) Tobin
Mr. James R (Jim) Tobin
Lead Independent Director
Lead Independent Director
--
--
Ms. C. Ann Merrifield
Ms. C. Ann Merrifield
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: vie., 16 de may
Hora de actualización: vie., 16 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Perceptive Advisors LLC
19.25%
North Bridge Venture Partners
8.89%
BlackRock Institutional Trust Company, N.A.
4.53%
The Vanguard Group, Inc.
2.66%
Samsara BioCapital, LLC
2.10%
Other
62.57%
Estadísticas de accionistas
Accionista
Proporción
Perceptive Advisors LLC
19.25%
North Bridge Venture Partners
8.89%
BlackRock Institutional Trust Company, N.A.
4.53%
The Vanguard Group, Inc.
2.66%
Samsara BioCapital, LLC
2.10%
Other
62.57%
Tipo
Accionista
Proporción
Private Equity
19.25%
Venture Capital
10.98%
Investment Advisor
6.77%
Investment Advisor/Hedge Fund
6.14%
Hedge Fund
4.27%
Research Firm
0.88%
Individual Investor
0.83%
Pension Fund
0.24%
Bank and Trust
0.08%
Other
50.56%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
166
33.99M
51.29%
-25.72M
2024Q4
169
34.27M
52.36%
-23.86M
2024Q3
170
41.74M
67.36%
-17.33M
2024Q2
155
41.35M
70.46%
-15.27M
2024Q1
137
54.47M
94.92%
+4.29M
2023Q4
113
50.90M
93.69%
+8.93M
2023Q3
96
40.42M
84.31%
-314.10K
2023Q2
103
42.33M
88.17%
+11.26M
2023Q1
124
25.98M
81.63%
-890.12K
2022Q4
126
26.32M
82.72%
+975.89K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
12.76M
19.36%
--
--
Dec 31, 2024
North Bridge Venture Partners
5.89M
8.94%
--
--
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
3.08M
4.68%
+98.60K
+3.31%
Dec 31, 2024
The Vanguard Group, Inc.
1.79M
2.71%
+8.16K
+0.46%
Dec 31, 2024
Samsara BioCapital, LLC
1.97M
2.98%
-814.57K
-29.30%
Dec 31, 2024
Ikarian Capital LLC
1.06M
1.61%
+1.32K
+0.12%
Dec 31, 2024
Geode Capital Management, L.L.C.
885.97K
1.34%
+117.58K
+15.30%
Dec 31, 2024
Nantahala Capital Management, LLC
628.07K
0.95%
+628.07K
--
Sep 30, 2024
Two Sigma Investments, LP
595.50K
0.9%
-147.35K
-19.84%
Dec 31, 2024
Waksal (Harlan W)
536.97K
0.82%
+275.00K
+104.98%
Feb 28, 2025
Ver más
ETFs relacionados
Hora de actualización: hace 6 horas
Hora de actualización: hace 6 horas
Nombre
Proporción
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver más
ProShares Hedge Replication ETF
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
